Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar, Received FDA Approval for Treating Different Forms of Inflammatory Diseases | Bentham Science Publishers

2000

Volume 22, Issue 4

ISSN: 1871-5230
E-ISSN: 1875-614X

s Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar, Received FDA Approval for Treating Different Forms of Inflammatory Diseases
By Vinod K. Rajana, Sudha Madhavi Penumaka, Cevella Saritha, Velayutham Ravichandiran and Debabrata Mandal
Source: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Volume 22, Issue 4, Dec 2023, p. 273 - 275
DOI: https://doi.org/10.2174/0118715230273701231102100558
- Available online: 01 Dec 2023

Preview this article:

There is no abstract available.

© Bentham Science Publishers

Article metrics loading...

/content/journals/aiaamc/10.2174/0118715230273701231102100558

2023-12-01

2025-09-05

From This Site

/content/journals/aiaamc/10.2174/0118715230273701231102100558

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Loading full text...

Full text loading...

/content/journals/aiaamc/10.2174/0118715230273701231102100558

Article Type: Other

Keyword(s): Adalimumab biosimilar; inflammation; rheumatoid arthritis; TNF receptor; TNFα; yuflyma

Most Cited Most Cited RSS feed

This is a required field

Please enter a valid email address

Approval was a Success

Invalid data

An Error Occurred

Approval was partially successful, following selected items could not be processed due to error

Please enter a valid_number test